Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell
00

Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell

Nov 17, 2026

On November 17, 2026, biotechnology startup Marrow Therapeutics emerged from stealth with $173 million in Series A and B financing to develop MAR-101, an injectable siRNA transferrin antibody bioconjugate for sickle cell disease and beta thalassemia. Existing gene therapies like Casgevy and Lyfgenia require complex stem cell modification, chemotherapy, and high costs, limiting access in sub-Saharan Africa where most patients live. MAR-101 aims to offer a safer, globally accessible alternative.

Marrow Therapeutics emerges with funding for lead candidate

  • ▪Biotechnology startup Marrow Therapeutics emerged from stealth on November 17, 2026, raising $173 million in combined Series A and Series B financing from Eleven investors, including Scion Life Sciences, OrbiMed, and venBio
  • ▪Marrow Therapeutics plans to use its $173 million funding to advance its lead drug candidate MAR-101 for sickle cell disease and beta thalassemia and to build out its manufacturing capabilities

Mechanism and advantages of MAR-101

  • ▪Marrow Therapeutics' lead candidate MAR-101 is a transferrin antibody bioconjugate that links small interfering RNA to an antibody, targeting bone marrow iron receptors to reactivate fetal hemoglobin production through simple injections
  • ▪Unlike stem cell gene therapies that require one-time laboratory cell modification, Marrow Therapeutics' MAR-101 can be administered via repeated injections should treatment effects wane

Statements from CEO Romesh Subramanian

  • ▪Marrow Therapeutics Chief Executive Officer Romesh Subramanian stated that the company is developing MAR-101 to provide a safer, efficacious, and globally accessible treatment alternative for patients with inherited blood disorders
  • ▪Marrow Therapeutics Chief Executive Officer Romesh Subramanian stated that preclinical data has given the company confidence to advance lead candidate MAR-101 into clinical trials

3 sources

BioPharma Dive
Marrow sets out to challenge genetic medicines for severe blood diseases
View source article
STAT News
With $173 million, new startup takes aim at sickle cell
View source article
Endpoints
Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell
View source article

Featured stories

View more in Biotech innovation

Ramp in talks for funding at $70B valuation led by Coatue and Thrive

Nov 17, 2026 · 2 sources

Noeri raises $110M to build self-improving AI systems

Nov 16, 2026 · 3 sources

Story comments

Loading comments…

Related entities

Beta-thalassemiaSickle Cell disease

Topics

Biotech innovationGene therapyDrug developmentHematologyBiotechnologyBiotech startupGenetic disordersVenture capital funding

Featured stories

View more in Biotech innovation

Ramp in talks for funding at $70B valuation led by Coatue and Thrive

Nov 17, 2026 · 2 sources

Noeri raises $110M to build self-improving AI systems

Nov 16, 2026 · 3 sources